The global human rabies vaccine market was valued at USD 987.77 Million in 2025 and is expected to grow at a CAGR of 4.50%, reaching USD 1533.98 Million by 2035. The market growth is driven by increasing government immunization programs, rising awareness about post-exposure prophylaxis, and the expansion of advanced vaccine formulations. Growing demand in emerging economies, coupled with improvements in distribution channels and healthcare infrastructure, is anticipated to support market value during the forecast period. Ongoing research into novel vaccine delivery methods further enhances growth potential.
Base Year
Historical Period
Forecast Period
In July 2025, the CDC updated rabies pre-exposure prophylaxis guidelines, simplifying dose schedules and risk-based recommendations. These measures are expected to increase vaccine adoption, thereby, driving growth in the market.
One of the major market trends include the increasing adoption of post-exposure prophylaxis for rabies prevention. For instance, in May 2025, Australian guidelines emphasized immediate wound management, rabies vaccination, and human rabies immunoglobulin administration to mitigate infection risks, supporting market growth.
The key players are boosting market growth by supporting post-exposure prophylaxis, mass vaccination, public awareness campaigns, and improved surveillance, enhancing accessibility, adherence, and overall effectiveness of rabies prevention programs globally.
Compound Annual Growth Rate
4.5%
Value in USD Million
2026-2035
*this image is indicative*
The human rabies vaccine plays a vital role in protecting individuals at risk of rabies exposure, particularly in regions where the disease remains a public health concern. Its demand is driven by rising awareness, government immunization programs, and collaborative initiatives to eliminate rabies globally. The global human rabies vaccine market has witnessed steady growth, supported by technological advancements and expanded access in developing regions. The market is poised to reach USD 1533.98 Million by 2035, reflecting increasing investments, improved distribution networks, and continued efforts to reduce the rabies.
Rising Rabies Incidence to Elevate the Growth in the Market
A key driver of the market is the alarming number of rabies-related deaths worldwide, highlighting the critical need for prevention and vaccination. According to the Centers for Disease Control and Prevention (CDC) in July 2025, rabies claims around 70,000 lives annually, with over 99% of human cases outside the United States linked to dog bites. Wildlife such as bats, foxes, and skunks also act as carriers in various regions, worsening the burden. These challenges, combined with rising awareness and global vaccination initiatives, are expected to accelerate sustained growth in the market.
The market is experiencing key trends, including the expansion of access programs and increasing global awareness through comprehensive vaccination campaigns.
Expanding Access Programs Expected to Boost Market Value
A notable trend in the global human rabies vaccine market is the growing emphasis on equitable access through international collaborations. In June 2024, Gavi, the Vaccine Alliance, announced a large-scale initiative with the WHO and UAR to provide human rabies vaccines for post-exposure prophylaxis across more than 50 countries, particularly targeting underserved communities in Africa and Asia, where 95% of deaths occur. Such coordinated efforts are set to strengthen distribution channels and significantly boost market growth worldwide.
Rising Global Awareness and Vaccination Campaigns to Propel Human Rabies Vaccine Market Demand
The market is witnessing growth driven by increasing awareness campaigns and large-scale vaccination initiatives aimed at preventing rabies. Mass canine vaccination, combined with improved access to pre- and post-exposure prophylaxis, has demonstrated significant success in reducing human rabies cases. For instance, in September 2024, World Rabies Day highlighted efforts in the Americas, where coordinated programs by PAHO and WHO reduced human rabies transmitted by dogs by approximately 98%, from 300 cases in 1983 to five in 2024. Such initiatives are expected to further boost demand for human rabies vaccines worldwide.
Vero Cell Vaccine Anticipated to Dominate Product Type Segment
By product type, the market is segmented into baby hamster kidney (BHK) vaccine, purified chick embryo cell rabies vaccine, vero cell rabies vaccine, and other variants. Among these, vero cell rabies vaccine is likely to hold a significant share in the market due to its proven safety, affordability, and suitability for both pre- and post-exposure prophylaxis. Supporting this trend, in April 2025, the Serum Institute of India launched a serum-free iterative rabies vaccine, which builds on Vero cell–based advancements, further strengthening its dominance by addressing allergic risks and reducing dependence on animal-derived components. This highlights Vero Cell vaccines’ continued leadership in driving innovation and accessibility in rabies prevention.
The market is divided into regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. Among these, North America is expected to dominate the market, supported by strong preventive measures and robust vaccination programs. According to the Centers for Disease Control and Prevention (CDC), around 10 human rabies deaths occur each year in the United States. However, with over 6 million Americans reporting animal bites annually and approximately 100,000 requiring post-exposure prophylaxis (PEP), the region continues to generate strong vaccine demand to maintain control and prevent outbreaks.
The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Sanofi SA has been a key player in the human rabies vaccine market since 1977, actively developing, manufacturing, and distributing vaccines worldwide to address ongoing public health needs. With rabies still causing various deaths annually, Sanofi emphasizes prevention and post-exposure immunization, particularly in vulnerable populations. The company’s continued innovation reinforces its vital role in combating rabies globally.
GSK plc, a leading global biopharmaceutical company, continues to strengthen its role in the vaccine market through innovation and partnerships. In June 2025, GSK licensed its Shigella vaccine candidate to Bharat Biotech International Limited, building on their established collaboration in infectious disease prevention. With Bharat Biotech’s portfolio including rabies vaccines, this partnership underscores GSK’s indirect involvement in advancing solutions relevant to the global human rabies vaccine market.
Merck & Co., Inc., through its Merck Animal Health division, plays an active role in the global human rabies vaccine market by supporting large-scale rabies elimination initiatives. In 2024, the company announced continued donations of its NOBIVAC® rabies vaccines to Mission Rabies, reinforcing its long-standing commitment to prevention. With decades of involvement, Merck contributes significantly to global rabies control and public health protection.
Boehringer Ingelheim International GmbH is a global biopharmaceutical leader focused on advancing human and animal health through innovation. The company emphasizes preventive care and vaccines. In July 2023, its Indian division launched the “Stop Rabies” initiative in Mumbai, donating 30,000 doses of its anti-rabies vaccine Rabisin® in collaboration with PPAM and BMC, reinforcing its “One Health” approach and supporting global rabies elimination goals by 2030.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Pfizer Inc., Bharat Biotech, AstraZeneca plc, CSL Behring, Grifols SA, and Shuanglin Bio-Pharmaceutical Co., Ltd.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Product Type
Market Breakup by Vaccination Type
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Distribution Channel
Market Breakup by Region
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Vaccination Type |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share